A Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0292 Following Single Ascending Dose Administration to Healthy Japanese Participants
Latest Information Update: 02 Nov 2025
At a glance
- Drugs AZD 0292 (Primary)
- Indications Bronchiectasis
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 02 Nov 2025 New trial record